

9-17-2021

Development of a recombinant vaccine against human onchocerciasis.

David Abraham
Thomas Jefferson University

John Graham-Brown
University of Liverpool

Darrick Carter
PAI Life Sciences Inc

Sean A. Gray
PAI Life Sciences Inc

Follow this and additional works at: <https://jdc.jefferson.edu/mifp>
Jessica A. Hess

 Part of Jefferson University Department of Microbiology and Immunology Commons, and the Medical Microbiology Commons

Let us know how access to this document benefits you

See next page for additional authors

Recommended Citation

Abraham, David; Graham-Brown, John; Carter, Darrick; Gray, Sean A.; Hess, Jessica A.; Makepeace, Benjamin L.; and Lustigman, Sara, "Development of a recombinant vaccine against human onchocerciasis." (2021). *Department of Microbiology and Immunology Faculty Papers*. Paper 142.
<https://jdc.jefferson.edu/mifp/142>

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's [Center for Teaching and Learning \(CTL\)](#). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Department of Microbiology and Immunology Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.

Authors

David Abraham, John Graham-Brown, Darrick Carter, Sean A. Gray, Jessica A. Hess, Benjamin L. Makepeace, and Sara Lustigman

Development of a recombinant vaccine against human onchocerciasis

David Abraham, John Graham-Brown, Darrick Carter, Sean A. Gray, Jessica A. Hess, Benjamin L. Makepeace & Sara Lustigman

To cite this article: David Abraham, John Graham-Brown, Darrick Carter, Sean A. Gray, Jessica A. Hess, Benjamin L. Makepeace & Sara Lustigman (2021) Development of a recombinant vaccine against human onchocerciasis, Expert Review of Vaccines, 20:11, 1459-1470, DOI: [10.1080/14760584.2021.1977125](https://doi.org/10.1080/14760584.2021.1977125)

To link to this article: <https://doi.org/10.1080/14760584.2021.1977125>



© 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.



Published online: 17 Sep 2021.



Submit your article to this journal [↗](#)



Article views: 850



View related articles [↗](#)



View Crossmark data [↗](#)

REVIEW



Development of a recombinant vaccine against human onchocerciasis

David Abraham^a, John Graham-Brown^b, Darrick Carter^c, Sean A. Gray^c, Jessica A. Hess^a, Benjamin L. Makepeace^b and Sara Lustigman^d

^aDepartment of Microbiology and Immunology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USA; ^bInstitute of Infection, Veterinary & Ecological Sciences, University of Liverpool, Liverpool, UK; ^cPAI Life Sciences Inc, Seattle, WA, USA; ^dLaboratory of Molecular Parasitology, Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY, USA

ABSTRACT

Introduction: Human onchocerciasis caused by the filarial nematode parasite *Onchocerca volvulus* remains a major cause of debilitating disease infecting millions primarily in Sub-Saharan Africa. The development of a prophylactic vaccine, along with mass drug administration, would facilitate meeting the goal of onchocerciasis elimination by 2030.

Areas covered: Models used to study immunity to *Onchocerca* include natural infection of cattle with *Onchocerca ochengi* and *O. volvulus* infective third-stage larvae implanted within diffusion chambers in mice. A vaccine, comprised of two adjuvanted recombinant antigens, induced protective immunity in genetically diverse mice suggesting that it will function similarly in diverse human populations. These antigens were recognized by immune humans and also induced protective immunity against *Brugia malayi*. We describe the development of a fusion protein composed of the two vaccine antigens with the plan to test the vaccine in cows and non-human primates as a prelude to the initiation of phase 1 clinical trials.

Expert opinion: The adjuvanted *O. volvulus* vaccine composed of two antigens Ov-103 and Ov-RAL-2 was shown to be consistently effective at inducing protective immunity using multiple immune mechanisms. The vaccine is ready for further evaluation in other animal models before moving to clinical trials in humans.

ARTICLE HISTORY

Received 2 June 2021
Accepted 2 September 2021

KEYWORDS





Onchocerca volvulus; *Onchocerca ochengi*; fusion protein; recombinant vaccine antigens; onchocerciasis; TOVA; vaccine against onchocerciasis

1. Onchocerciasis – the need for a prophylactic vaccine

Human onchocerciasis ('river blindness'), caused by the filarial nematode parasite *Onchocerca volvulus*, is a major cause of infectious blindness, skin disease, and chronic disability. It infects many millions worldwide with 99% of the cases sustained in 31 countries of Sub-Saharan Africa- resulting in widespread vision impairment and blindness. Current estimates put 120 million people at risk [1,2]. The Global Burden of Disease Study estimated in 2017 that there were 20.9 million people infected worldwide, of which 14.6 million had skin disease and 1.15 million had vision loss [3,4] (Figure 1). Importantly, it has become apparent in recent years that onchocerciasis-associated epilepsy (OAE) is also an important public health problem caused by onchocerciasis. In a recent door-to-door survey in Mvolo, an onchocerciasis endemic region in South Sudan, the prevalence of epilepsy in this population was higher (5.1%) than blindness (2.8%) [5].

Long the focus of efforts to alleviate morbidity and lost productivity, onchocerciasis has been identified by the World Health Organization as a potential candidate for global elimination through mass drug administration (MDA) of the donated drug ivermectin (IVM) (Mectizan®) [6–8]. This plan

began in the 1990's as the 'Onchocerciasis Elimination in the Americas' and later by the 'African Programme for Onchocerciasis Control' (APOC) in 1995 with a World Health Assembly goal to establish community-based sustainable treatments of 50 million people in 19 African countries having meso- and hyper-endemicity by 2010 [7,9]. In 2015, the mission of onchocerciasis elimination for Africa was passed from APOC to its successor, the Expanded Special Programme for the Elimination of Neglected Tropical Diseases [10]. Addition of vegetation 'slash and clear' for vector control, as a supplement to MDA, has been proposed as an adjunct to accelerate elimination of onchocerciasis [11]. However, numerous and formidable technical and logistical obstacles must still be overcome before the ambitious goal of elimination by 2030 can be achieved in Africa [9,12]. These include (1) MDA of IVM cannot be used in 11 Central African countries co-endemic with *Loa loa* infections due to the risk of severe adverse events [13–16]; (2) The few drugs active against the adult stage of the parasite are not used for MDA, and IVM, as well as the recently approved drug moxidectin, are only effective against microfilariae [17]; (3) The practical complication of treating people for 14 to 35 years compounds the difficulty of implementing the plan [7,8]; (4) Experimental studies indicate that susceptibility to reinfection may increase after treatment, further

CONTACT David Abraham  David.Abraham@jefferson.edu  Department of Microbiology and Immunology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pa, USA; Sara Lustigman  slustigman@nybc.org  Laboratory of Molecular Parasitology, Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY, USA

© 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (<http://creativecommons.org/licenses/by-nc-nd/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.

Article highlights

- A vaccine composed of two antigens *Ov*-103 and *Ov*-RAL-2 in combination with the adjuvants alum or Advax-2 was shown to consistently induce protective immunity to *O. volvulus* in mice.
- The vaccine was effective at inducing protective immunity in genetically diverse mice and against other filarial worms.
- Trials are ongoing testing the vaccine against natural infection of cows with *O. ochengi*
- A fusion protein comprised of the two antigens is undergoing testing in mice, cows and non-human primates prior to clinical trials

complicating the disruption of the transmission cycle [18–20]; and finally (5) The potential emergence of IVM-resistant *O. volvulus*, may limit the long-term effectiveness of MDA and, in time, undermine all of the gains achieved by onchocerciasis control programs [21–29]. Originally developed for veterinary use, IVM was re-purposed for use as a microfilaricidal drug in humans, initially to great effect [30,31]. While current evidence for IVM resistance in *O. volvulus* is far from definitive, it is quite clear that sub-optimal responses to IVM in the treatment of river blindness have been identified, in particular, as manifested by faster rates of microfilarial skin repopulation linked to decreased effects of IVM on female worm fecundity [32]. It should be noted that IVM was first used for many years to prevent heartworm disease caused by the filarial parasite *Dirofilaria immitis* in domestic dogs and cats, but it has been demonstrated that IVM-resistant *D. immitis* is already circulating in the United States [33]. Complicating the challenges with relying only on MDA with IVM is that IVM is not administered to children under 5 years old and a macrofilaricidal drug, doxycycline, cannot be given to children under 9 thus limiting the indications for these two drugs. In addition, doxycycline requires 6 weeks of treatment to be effective which further diminishes its utility [34]. Thus, children are not only vulnerable to infection but become reservoirs for transmission [35].

The successes of the control programs must be weighed against the fact that since 1995 only a 31% reduction in the incidence of onchocerciasis has been achieved in Africa [2,36–38]. In 2016, APOC called for 1.15 billion treatments until 2045, though many neglected tropical disease experts doubt that onchocerciasis can ever be eliminated through MDA with IVM

alone, due to the aforementioned limitations [39,40]. Moreover, due to the high cost, MDA is not currently implemented in areas of low prevalence in Africa. This may contribute to continued transmission through human migrations that may result in reintroducing the parasite back into regions where it had once been controlled [16].

It is clear to the public health community dedicated to the control of this disease that additional tools are critically needed to support the existing control measures [41–43]. It is equally clear that an effective vaccine aimed at preventing infection with *O. volvulus* infective larvae (L3) would be an essential, additional component in the effort to control onchocerciasis. Moreover, it is recognized that a high burden of OAE in onchocerciasis endemic areas with high ongoing transmission adds to the importance of preventing new infections by a vaccine targeting children under 5 years old who are at risk for developing OAE including nodding syndrome [44]. Vaccine development against infection with *O. volvulus* has been the subject of much thought and work in the past through the funding (1985–1999) from the Edna McConnell Clark Foundation [45–49]. This approach was endorsed by APOC that strongly encouraged the development of a prophylactic vaccine as part of new tools needed to meet the onchocerciasis elimination agenda [49,50]. This was further restated in a recent report listing the new global targets for NTDs in the WHO roadmap 2021–2030 [51]. In 2015, an international consortium launched a new global initiative, known as TOVA – The Onchocerciasis Vaccine for Africa [52]. TOVA is primarily focused on a vaccine comprised of recombinant protein(s) and various adjuvants as described below, with the goal of developing a vaccine that meets the desired target product profiles [53]. It is envisioned that the preventive *Onchocerca* vaccine will be used to partially protect vulnerable populations, children under 5 years of age who have not yet had access to MDA with IVM, against infection with L3. Consequently, the adult worm burden and the number of microfilariae produced by adult female worms will be reduced, resulting in reduced pathology and rates of transmission. Based on mathematical modeling, with the assumption that such a vaccine has an initial prophylactic efficacy of 50% and a therapeutic efficacy of 90% against microfilariae, the vaccine would have a beneficial impact in onchocerciasis–loiasis co-endemic areas by markedly reducing microfilarial loads in the



Figure 1. Stages of *Onchocerca volvulus* and clinical presentation.

(a) Infective third-stage larvae (L3s) recovered from infected black flies (Photo credit: Sara. Lustigman, New York Blood Center). (b) *O. volvulus* female worm released from nodule by collagenase digestion (Photo credit: Adrian JF Luty, French National Research Institute for Sustainable Development). (c) Subcutaneous fibrotic Nodule found on a child from Ghana containing adult *O. volvulus*. (Photo credit: Peter Soboslay, PLOS Neglected Tropical Diseases: Of Mice, Cattle, and Humans: The Immunology and Treatment of River Blindness).

young (under 20 years) age groups, which are a major reservoir for transmission [35]. Thus, an anti-larval vaccine would support further reduction in transmission and as a result ensure the success of the existing MDA with IVM. At the same time, vaccination would allow for diminished subsequent use of drugs and forestall drug resistance.

2. Foundation Studies – immunity in humans to *O. volvulus* and the development of animal models for the study of protective immunity

The feasibility of an anti-*O. volvulus* larvae vaccine is supported by uncovering two distinctive expressions of anti-L3 protective immunity within the *O. volvulus* endemic population: **(1)** Immunity that impedes the development of patent infections (microfilaria positive) in the putatively immune (PI) individuals (*i.e.* individuals that had no clinical manifestations of the disease, even though they lived for at least 10 years within regions where onchocerciasis is endemic and were exposed to high transmission rates of infection) [54–57]; **(2)** Concomitant immunity to *O. volvulus* L3, which develops in the patently infected (INF) individuals with increasing age and is independent of the immune responses that are induced by the adult worms and microfilariae associated with patent infection. Concomitant immunity prevents most of the newly acquired L3 infections from developing and results in a stable adult worm burden in the INF [18,58,59]. This immunity is not directed against the adult or the microfilaria stages of the parasite. Some of the mechanisms of acquired protective immunity against *O. volvulus* infection in humans (reviewed in [45,60,61]) were shown to be associated with their ability to mount mixed Th1/Th2 responses against *O. volvulus* L3 and/or molting L3 [57,59], as well as the presence of cytophilic antibodies that together with the cytokines produced, induce efficient anti-L3 antibody-dependent cell mediated cytotoxicity (ADCC) reactions against L3 [59,62–70].

Research on the biology, pathology and immunology of *O. volvulus* has been limited by the host range of the infection, consisting of only naturally infected humans and gorillas, although chimpanzees and mangabey monkeys are partially permissive to patency in laboratory settings [71,72]. The mean pre-patent period in primates ranges from 12 to 23 months that adds to the limitations of the primate hosts for use in experimental studies [71]. In addition, after skin penetration, the L3 of *O. volvulus* migrates throughout the tissues making accurate recovery of the parasites from infected animals challenging. To overcome these impediments, a system was developed in which L3 were implanted subcutaneously within diffusion chambers, which were designed to contain larvae *in vivo* without restricting the infiltration of host cells into the parasite microenvironment. This system allows recovery of early larval stages and the analysis of the local innate and adaptive immune responses to the infections. Diffusion chambers containing L3 were implanted in primates including chimpanzees, mangabey monkeys, rhesus monkeys, and squirrel monkeys as well as rodents – including 4 inbred strains of rats, 6 inbred strains of mice, and gerbils. The L3 developed into fourth-stage larvae (L4) and increased in length over the 63 days *in vivo* in all tested hosts except for larvae implanted

in squirrel monkeys and in rats. Importantly, equal survival rates were observed with fresh and cryopreserved larvae [73]. The combination of mouse susceptibility, development of L3 into L4, efficient recovery of parasites and the use of cryopreserved larvae opened the door for the use of this model to identify protective vaccine candidates and to develop a prophylactic vaccine against the early stages of the infection. Importantly, the protective immunity that develops in humans shares many characteristics with those described in the mouse vaccine model, as discussed below [74].

As an alternative approach to studying *O. volvulus*, other species of *Onchocerca* have been identified but, unlike *O. volvulus*, most of these parasitize ungulates including domestic cattle [75]. While most of these are of negligible importance for animal health, they present a unique opportunity as model systems for studying human onchocerciasis, enabling the study of natural infection and transmission as well as protective immunity in a way that cannot otherwise be achieved outside human clinical trials.

Onchocerca ochengi is the most notable of these, sharing many key characteristics with *O. volvulus* in terms of its genome, biology, lifecycle and transmission including its arthropod vector (*Simulium damnosum s.l.*), the sedentary nodule-forming nature of adult females, microfilaridermia and presence of the endosymbiont *Wolbachia* [76–78]. Indeed, these two parasites are so similar it is hypothesized that *O. volvulus* evolved either directly from *O. ochengi* or another common cattle-infecting ancestor, jumping hosts in a speciation event coinciding with the recent introduction (in an evolutionary context) of domestic cattle to the African continent [79]. This theory is supported by numerous phylogenetic studies showing the close relationship of these two sister species [80,81]. Importantly in the context of vaccine development, this relationship also extends to antigenic homology [82,83]. Accordingly, a zooprophylactic effect against infection with *O. volvulus* has been inferred epidemiologically in humans that results from natural exposure to *O. ochengi* in co-endemic regions [84].

The bovine-*O. ochengi* natural transmission model is therefore a valuable tool for human onchocerciasis research allowing the evaluation and quantification of key aspects of infection and the lifecycle, including disease kinetics, adult worm and microfilarial burdens, female worm fecundity and viability. It has been also used extensively to aid investigations into basic parasite biology, including host-parasite interactions, vector biology and epidemiology as well as more applied clinical studies focused on testing vaccine candidates and efficacy trials of micro- and macrofilaricidal drugs [85–95] (Figure 2).

3. Can animals be immunized against infection with *Onchocerca* spp and develop adaptive protective immunity?

3.1. *O. ochengi* bovine model

Naturally acquired immunity to *O. ochengi* has been demonstrated in cattle to be related to a number of factors including host heterogeneity. A small proportion of animals in endemic



Figure 2. The bovine-*Onchocerca ochengi* natural transmission model offers a number of opportunities for the study vaccines against human onchocerciasis.

(a.) Natural exposure to infection and quantification of the level of challenge through bait-capture of *Simulium damnosum s.l.* (circled), (b.) Longitudinal observation of infection kinetics including emergence of adult female nodules in situ (arrow) and associated clinical parameters, (c.) Quantification of microfilarial burdens through skin snips, and (d.) Assessment of adult worm biometrics including size, viability and fecundity via nodulectomies (Photo credits: John Graham-Brown, University of Liverpool).

regions demonstrate a putative immunity (similar to observations from human populations). Female cattle and older animals demonstrate an increased level of immunological protection against microfilaridermia compared to male and younger animals, respectively [87,89,96].

Attempts to induce immunity through experimental immunizations have also yielded positive results. Cattle immunized with irradiated *O. ochengi* L3 demonstrated an 84% reduction in adult female worm burdens following experimental challenge and 53% reduction in microfilarial burdens following natural challenge compared to unvaccinated control animals [89]. Similarly, following an initial experimental 'immunization' with live *O. volvulus* L3, cattle demonstrated an 86% reduction in *O. ochengi* adult female worm burdens compared to control animals following subsequent experimental challenge with L3 [97]. In 2009, a study evaluating the co-administration of eight recombinant *O. volvulus* antigen candidates, each formulated in Freund's or alum adjuvants, had shown that although no significant difference in adult female worm burdens between vaccinated and unvaccinated animals following subsequent exposure to natural infections was found, there was a significant reduction in the frequency of microfilaridermia present in vaccinated versus unvaccinated control animals [95]. This reduction was associated with antigen-specific serum IgG1 (Th2-associated antibody) and IgG2 (Th1-associated antibody) responses [98]. The presence of IgG2 isotype antibody is of particular interest in vaccinated protected cattle, as this isotype is commonly associated with Th1-type immune responses and ADCC activity in cattle [99]. The outcome of this vaccine study is highly important because only the microfilarial stage is responsible for transmission and disease symptoms in onchocerciasis. Therefore, even if a vaccine is only effective against microfilariae, it could still play a key role in elimination programs by reducing transmission potential [35].

3.2. *O. volvulus* mouse model

The mouse diffusion chamber model was validated in multiple studies as a valuable tool for the development of a vaccine against *O. volvulus*. Initially, it was determined that protective immunity directed at larvae within diffusion chambers could

develop in mice following vaccination. Statistically significant levels of protective immunity were induced in BALB/cByJ mice following immunization with irradiated L3 [100]. Protective immunity induced by irradiated L3 was dependent on IL-4- and IL-5, and independent of IFN- γ , suggesting that protective immunity was based on a Th2 CD4⁺ T cell response [101,102]. This conclusion was confirmed by studies that demonstrated that the mechanism of protective immunity induced by irradiated L3 required IgE and eosinophils [103,104].

4. Identification and selection of the recombinant *O. volvulus* vaccine antigens

Although irradiated L3 were shown to consistently induce significant levels of protective immunity to *O. ochengi* in cows and to *O. volvulus* in mice, it was clear that use of L3 recovered from infected black flies would never be a realistic source of antigen for a vaccine to be used in human populations. To overcome this obstacle, two basic strategies were used to identify and clone *O. volvulus* target vaccine antigens [53]. The first exploited the potential involvement of antibodies in protective immunity by immunoscreening various *O. volvulus* cDNA libraries to identify target proteins. The second strategy identified and isolated molecules thought to be essential during the infection process. Twelve of 26 recombinant antigens identified by the first strategy and four of 18 identified by the second strategy were confirmed to induce partial but statistically significant protection in the presence of an adjuvant (alum, block copolymer, or Freund's complete adjuvant) or using a DNA immunization when tested in the *O. volvulus* mouse model [61]. Each of these antigens was produced and tested under unique conditions. The next step in the development of the *O. volvulus* vaccine was to produce antigens in one laboratory under standardized conditions so that the antigens could be compared to each other for vaccine efficacy. From the list of protective antigens, eight were selected using stringent scoring criteria and then produced in two different expression systems, *Escherichia coli* and *Pichia pastoris*. All of the immunizations were with alum as the adjuvant to favor a Th2 response. The recombinant antigens Ov-103 produced by *E. coli* and Ov-RAL-2 produced by *P. pastoris* emerged as lead vaccine candidate antigens [105]. Both proteins are localized on the

surface and glandular esophagus of L3 as well as in the hypodermis and cuticle of adult worms and on the surface of microfilariae [106]. As the protective immunity induced by the two antigens was partial, it was hypothesized that immunizing mice with both antigens would enhance the protective immune response. Mice were immunized with either a fusion or co-administration of the two antigens. IgG antibody titers were higher with the combined antigens than with individual antigens demonstrating that they were not immunologically competitive. This is in contrast to other combined *O. volvulus* vaccine antigens that were found to compete with each other, resulting in reduced antibody titers [107]. However, the levels of protective immunity induced by the co-administered vaccines were not enhanced as compared to protection in mice immunized with the individual antigens. Importantly vaccinated mice did not develop IgE responses to either of the antigens [105]. To determine the role of antibody in the protective immune response, AID^{-/-} mice, which do not produce IgG, were immunized with either Ov-103 or Ov-RAL-2 formulated with alum. In the absence of parasite-specific IgG immunized AID^{-/-} mice did not develop protective immunity. Furthermore, significant levels of parasite killing in Ov-103 and Ov-RAL-2 vaccinated mice only occurred when cells entered the parasite microenvironment. Based on these studies, it was concluded that protective immunity induced by Ov-103 and Ov-RAL-2 was dependent on crosstalk between IgG and immune cells which suggests an ADCC-dependent mechanism [108].

It was next hypothesized that the efficacy of an *Onchocerca* vaccine could be amplified if the type of immune responses induced by the vaccine were expanded. To test this hypothesis, mice were immunized with Ov-103 and Ov-RAL-2 independently or co-administered in combination with five different adjuvants known to induce Th1, Th2 or combined Th1/Th2 responses. The highest levels of larval killing were achieved in mice immunized with the two antigens each formulated with delta inulin and CpG oligodeoxynucleotide (ODN)-based adjuvant AdvaxTM-2 (Advax-2) as the adjuvant [109]. This vaccine induced significant Th2-associated IgG1 and Th1-associated IgG2a/b antibody responses as well as combined Th2 cytokines and IFN- γ in recall responses, indicating the induction of a mixed Th1/Th2 response. Both IgG1 and IgG2 mouse antibodies are cytophilic and could participate in ADCC [98]. Immunization with the co-administered vaccines increased antibody endpoint titers, yet correlation analyses comparing parasite recovery numbers and endpoint titers did not reveal consistent significant levels of statistical correlation. Importantly, the two antigens appeared to act collaboratively, boosting the antibody response to the reciprocal antigen and suggested that Ov-103 and Ov-RAL-2 induce two unique but synergistic protective killing mechanisms [110].

5. Validating the Ov-103 and Ov-RAL-2 *Onchocerca* vaccine for advanced preclinical development

5.1. Responses in humans to the Ov-103 and Ov-RAL-2 vaccine antigens

As Ov-103 and Ov-RAL-2 were identified as effective vaccine antigens in mice, it was important to verify that they were also associated with protective immunity in humans. Elevated IgG1

and IgG3 responses to Ov-103 and Ov-RAL-2 were seen in 86% of putatively immune individuals and 95% of individuals who have developed concomitant immunity with age. Moreover, human monospecific anti-Ov-103 antibodies but not anti-Ov-RAL-2 antibodies significantly inhibited the molting of L3 *in vitro* by 46% in the presence of naïve human neutrophils, while both monospecific anti-Ov-103 and anti-Ov-RAL-2 antibodies significantly inhibited the molting by 70–80% when cultured in the presence of naïve human monocytes. Interestingly, inhibition of molting by Ov-103 antibodies and monocytes was only partially dependent on contact with the cells, while inhibition of molting with Ov-RAL-2 antibodies was completely dependent on contact with the monocytes. These observations further suggest that the two antigens induce different mechanisms of protective immunity in humans [108].

The onchocerciasis vaccine is aimed at preventing the establishment of infection in children under 5 years old [52]. Accordingly, anti-Ov-103 and Ov-RAL-2 IgE responses were tested in 73 children of 1–5 years of age vs. 27 children aged 6–8 from a highly endemic region in Ghana. Two tests were used, ELISA and an antigen-specific IgE ImmunoCap assay that determines whether the antigen-specific IgE antibodies can mediate functional responses using a basophil histamine release assay [111,112]. None of the children under 5 had elevated functional Ov-103 or Ov-RAL-2 antigen-specific IgE responses, while 3/27 and 1/27 of the children 6–8 years of age had functional Ov-103 or Ov-RAL-2 antigen-specific IgE responses, respectively. Thus, continuous exposure to infective larvae with native Ov-103 and/or Ov-RAL-2 proteins did not elicit functional IgE in children under the age of 5 living in endemic regions in Ghana (Figure 3). This observation is promising and reduces the concern that these vaccine antigens would generate pathological atopic responses in vaccinated children (once proven to be safe in adults) as was seen with other helminth vaccines when tested in humans [111].

5.2. The candidate vaccine antigens also protect against other filarial worms

It is acknowledged that a significant limitation of the *O. volvulus*-mouse model is that the infection was restricted to diffusion chambers and that the length of the infection was limited to early larval stages. To validate the potency of the Ov-103 and Ov-RAL-2 vaccine, the efficacy of *Brugia malayi* orthologous antigens were tested in a *B. malayi*-gerbil model, where the full lifecycle of the parasite develops [106]. Gerbils were vaccinated with alum-adjuvanted Bm-103 and Bm-RAL-2 either individually, co-administered, or as a fusion protein of the two antigens. All three vaccine formulations induced protective immunity measured up to 150 days post-infection. The fusion protein or the co-administered vaccines induced more consistent and enhanced levels of protective immunity in gerbils to *B. malayi* infection with L3 as compared to levels achieved with the individual vaccines. Notably, the vaccines promoted reduced fecundity in female worms recovered from gerbils vaccinated with the fusion protein or with the co-administered vaccines, similar to what was observed in calves vaccinated with eight vaccines and exposed to fully developed *O. ochengi* patent infection [95]. Finally, serum from gerbils




Figure 3. Measurement of functional IgE responses in children to the antigens Ov-103 and Ov-RAL-2. Functional anti-Ov-103 (A) or Ov-RAL-2 (B) antigen-specific IgE responses were tested using antigen-specific ImmunoCap assays on sera from 73 children ages 1–5 and 27 children ages 6–8. The responses (kU/L) per age group are plotted. Cutoff (0.35 kU/L) for functional positive anti-Ov-103 (A) or Ov-RAL-2 IgE responses are marked by dashed lines.

vaccinated with the individual antigens, or with both antigens either co-administered or as a fusion protein, killed L3 *in vitro* in collaboration with peritoneal exudate cells [106]. Collectively the studies with *B. malayi* demonstrated that the two antigens induced protective immunity that was enhanced by immunization with both vaccine antigens and functioned through an antibody/cell-dependent mechanism.

5.3. Effect of host genetics on the efficacy of the Ov-103 and Ov-RAL-2 *Onchocerca* vaccine in mice

Experiments in the mouse-diffusion chamber model utilized a limited number of inbred mouse strains and it was questioned whether the vaccine would be effective in other genetic backgrounds. The ability of the vaccine to function in a wide variety of genetic backgrounds was considered to be critical as the vaccine is intended for use in genetically diverse human populations. The efficacy of the *O. volvulus* vaccine, composed of the two antigens Ov-103 and Ov-RAL-2 in combination with the adjuvant Advax-2, was tested in mice with disparate genetic backgrounds. Collaborative Cross recombinant inbred strains were crossed resulting in F1 hybrid CC Recombinant Inbred Intercross mice (CC-RIX). The resulting CC-RIX lines have increased genetic diversity yet are still homogenous and reproducible. The *O. volvulus* vaccine successfully induced protective immunity in male and female mice in 7 of 8 CC-RIX lines and in BALB/cByJ mice, suggesting that this vaccine can induce protective immunity across a wide array of genetic backgrounds. Innate protective immunity was observed in a single CC-RIX line; however, vaccination of this line did not enhance adaptive protective immunity following vaccination. Comprehensive analysis of effector cell recruitment, cytokines, chemokines and antibody responses revealed that each line of CC-RIX mice had a different adaptive immune response profile following vaccination and L3 challenge that consisted of a unique combination of multiple immune factors. Statistical analyses did not reveal correlations between individual factors or groups of factors and the presence of protective immunity. Studies in the CC-RIX mice demonstrated that the bivalent co-administered vaccine composed of Advax-

2-adjuvanted Ov-103 and Ov-RAL-2 was effective across a wide range of genetic backgrounds and suggests that the vaccine can induce several different types of protective immune mechanisms [113].

6. Clinical development of the onchocerciasis vaccine for humans

6.1. Novel lead candidate vaccine antigen construction

Following selection of Ov-103 and Ov-RAL-2 as the lead vaccine candidates, we combined them into a single fusion protein. This is commonly done for subunit vaccines and greatly simplifies process development, toxicology, and cGMP manufacturing resulting in significant time- and cost-savings. Two fusion proteins were generated and tested, Ov-Fus1 and Ov-Fus2. The Ov-103 and Ov-RAL-2 subunits were separated by a flexible, 12-amino-acid glycine/serine linker (GS) to promote independent folding of each subunit. Ov-Fus1 was designed as Ov-103-(GS)-Ov-RAL-2, whereas Ov-Fus2 was in the reverse orientation. Both fusions were produced in both *E. coli* and *P. pastoris*. Yeast expression was chosen due to its multiple production advantages including scalability, absence of endotoxin by-products, more native folding, and potential post-translational modifications. Protection studies in mice compared the two fusion constructs with readouts including vaccine-induced IgG/IgG1/IgG2 titers, cytokine production, and killing of L3 larvae within the diffusion chambers. Ov-Fus1 (*P. pastoris*) emerged as the lead protective fusion protein vaccine candidate for future clinical development. Producing a single fusion antigen would significantly simplify manufacturing, testing, and release of the vaccine antigen as well as administration to humans.

6.2. Process development of Ov-Fus1

Once the lead fusion vaccine antigen was selected, we initiated translational development of the candidate. Ov-Fus1 was designed *in silico* without a 6 × His affinity tag, codon optimized for production in *P. pastoris*, and cloned into the

vector pPICZa A. *P. pastoris* transformants were selected on YPD agar supplemented with 100 µg/mL zeocin, and individual subclones were screened for expression and secretion of the antigen. Lead clone (Ov-Fus1-9 H) with highest levels of antigen production was used to construct a research cell bank (RCB). Ov-Fus1 was initially produced by fermentation at the 5 L-scale and then using optimized conditions for up to 30 L-scale. Following fermentation, the clear supernatant was filter sterilized, concentrated, diafiltered (20 mM Tris pH 8.0) and the Ov-Fus1 protein purified using two ion-exchange chromatography steps performed in tandem; a negative pass, designed not to bind Ov-Fus1 while binding and removing non-target proteins followed by a second positive pass (Q Sepharose column) resulting in a purity of Ov-Fus1 of ~90%. The Ov-Fus1 was then polished to >98% purity using a hydrophobic interaction resin. Yields of Ov-Fus1 (~30 kDa) averaged 90 mg per liter with endotoxin levels below 100 EU/mg, which is well below the endotoxin levels allowed per injection (0.05 EU/mg) of a vaccine, assuming the onchocerciasis vaccine will be tested at 50 or 100 µg per injection. Purified Ov-Fus1 was tested for appearance, purity, sterility, endotoxin, and concentration before a Certificate of Testing was issued.

6.3. Vaccine trials against natural infection with *O. ochengi* in Cameroon

The Adamawa Region of north Cameroon is a major cattle-rearing area characterized by savanna grasslands and river systems. Unsurprisingly due to the abundance of host species and transmission sites, *O. ochengi* is endemic to this region, making it an ideal location to study the bovine-*O. ochengi* natural transmission model as well as the development of vaccine-induced protection against natural infection with *O. ochengi* [86,89,90,95,97].

Studying protective immune responses in cattle against *O. ochengi* is challenging because newly exposed, naive cattle are generally not maintained long enough to study acquired protective immunity or concomitant immunity; however, a few studies were able to characterize some of its aspects. Naturally acquired infections are typically long-lived, with most cattle continuing to acquire new infections over the course of their lifetime similar to what is observed in humans [4,87,89]. For instance, infected Cameroonian cattle with an initial geometric mean nodule load of ~80 acquired an average of 17 additional nodules when exposed to natural transmission for two additional years, whereas under 2 nodules on average were acquired by uninfected putative immune animals over the same timeframe [114]. Investigation of the bovine immune response following experimental infection of immunologically naïve animals with *O. ochengi* demonstrated that disease progression was also associated with a reduction in lymphoproliferative, parasite-specific IgG2 and pro-inflammatory cytokine (IL-2, IL-4 and IFN-γ) responses. Both naturally acquired and vaccine-induced-immunity offered some evidence of the types of immune responses required for protective immunity [95]. The heterogeneity of these naturally acquired and vaccine induced immune responses in cattle as well as the scarcity of bovine

immunological reagents makes a detailed characterization of immunity more challenging. Both Th1 and Th2 responses appear to be required for protective immunity against *O. ochengi* which is consistent with the findings from rodent models investigating vaccine-induced immunity using Ov-103, Ov-RAL-2 individually, co-administered, or as a fusion protein [105,108].

Current investigations in cattle are presently aimed at maximizing the potential protective effects of a co-administration of Ov-103 and Ov-RAL-2 or a Ov-Fus1-based adjuvanted vaccine in cattle against natural infection with *O. ochengi*, with the intention of inducing antigen-specific mixed Th1 and Th2 responses. To this end, a number of adjuvant formulations have been trialed using three distinct adjuvants, including Rehydralgel LV alum, a cattle-specific formulation of Advax-2 which induced a high degree of immunological protection in the experimental mouse *O. volvulus* model, and a veterinary water-in-oil-in-water (w/o/w) emulsion (Montanide™ ISA 206VG) which has previously been shown to induce protective immunity in cattle against the parasitic trematode *Fasciola hepatica* [110,115]. Preliminary immunogenicity studies consisting of a prime immunization followed by two booster inoculations (1 month apart) have indicated that immunization with the Montanide-adjuvanted vaccine was the most successful in inducing Th1/Th2-associated antibody responses.

The ability to observe and measure the vaccine induced immune responses present in cattle following immunization and subsequent natural challenge is central to the relevance of ongoing and future bovine vaccine trials. This not only gives us a better understanding of which components of the vaccine and resulting immune response are important for immunological protection, but also a deeper appreciation of the types of vaccine-induced immune responses to be expected in a heterogenous host population, thereby informing future human clinical trials. There are a number of well-established protocols for the investigation of bovine humoral and cellular responses, as well as analytical methods to help account for the variable nature of immune responses in phenotypically diverse populations [116]. Additionally, recent advances in omics-type approaches present opportunities for in-depth immunological analysis of clinical samples and *ex vivo* cell cultures, which have not previously been possible due to the remote field location of these trials [117]. Moreover, epitope-mapping techniques can be used with serum collected from vaccinated and putatively immune animals to identify specific natural- and vaccine-induced epitopes displaying a high degree of immunogenicity and associations with protective immunity for further research and development [118,119].

6.4. Selection of final animal model for verification of vaccine efficacy prior to testing in humans

While in many cases antigen selection can be performed using appropriate models of a pathogen's lifecycle, due to the complexity of the innate response triggered by adjuvants one must consider species-specific differences in receptor pathways – particularly when using combination adjuvants that

trigger both inflammatory and Toll-like receptors [120,121]. Mice tend to have very potent responses to innate agonists – perhaps due to their limited lifespan – which would make it beneficial for them to respond strongly to invading pathogens, as the risk of developing auto-immunity in a short time is low [122]. For this reason, considering higher order animal models is key to predictive modeling of an adjuvanted immune response in humans. Domesticated animals like cows and pigs may be a good choice as the close proximity of herds mimic human evolution of tribal and city living and thereby exposure to innate agonists. Notably, as outlined above, the protective responses in humans against *O. volvulus* and those in cattle against *O. ochengi* were shown to be similar. Despite this, and due mostly to evolutionary similarities, non-human primates (NHPs) are still considered among the best animal models for selecting the best adjuvanted vaccines for humans [123]. Other than their innate systems' similarity, the fact that some NHP species are natural hosts for other helminths and therefore suffer from diseases like schistosomiasis make them excellent models of vaccine efficacy and protection across helminth species [124,125]. For these reasons, as part of our current plans for the clinical development of the *Ov-Fus1* vaccine for onchocerciasis, we plan to verify protection data gathered in mice in NHPs prior to incurring the financial and time costs of human clinical development of an imperfect vaccine. Current design of our NHP studies includes various 'GO/NO GO' criteria. Among the 'GO' criteria would be induction of neutralizing IgG titers, demonstration of ADCC killing of L3 larvae (either *in vivo* or *ex vivo*), and induction of cytokines indicative of a robust Th1 response. Key 'NO GO' criteria will likely be failure to kill L3 larvae or reduce parasite burden or the induction of IgE antibodies.

6.5. Clinical trial criteria

A clinical path to successful deployment of an onchocerciasis vaccine has to take into consideration 'need, availability and cost' [126]. This breaks down into numerous factors that must be considered: The desired indication, the final target population, deployment conditions of the product, route of administration, and duration of the protective response. It is therefore imperative to develop a target product profile prior to entering clinical trials so that at the end of the human studies the data gathered will support the targeted deployment scenario. TOVA's present target product profile for an onchocerciasis vaccine in Africa assumes a > 50% efficacy at preventing establishment of incoming infections [35]. The target population are children under 5 years of age. For these reasons, the human clinical trials will be broken down into first testing the safety of the vaccine in a non-endemic area, *i.e.* a phase 1 human trial in adults to simply demonstrate safety of the vaccine formulation in individuals who have not been exposed to *O. volvulus*. Once this is complete, the clinical trial will be performed as a phase 1B safety study in endemic countries to demonstrate safety and immunogenicity in adult individuals who may have encountered the parasite in their lifetime. With this in mind, our clinical trial plan will begin by screening naïve patient sera for cross-reactivity to *Ov-Fus1* alone or to total *O. volvulus* lysates. Post-vaccinated sera will include

evaluating vaccine-specific responses, IgG titers and cytokine induction specific to *Ov-Fus1* and again compared to total *O. volvulus* lysates. Future studies would include phase 2 in adults where immunological markers of efficacy would be also collected (*e.g.* larvae-specific seroconversion as well as *in vitro* L3 inhibition of molting and/or killing by sera of vaccinated individuals in the presence of effector cells), as well as concomitant age de-escalation studies to reach the target dosing ages. The development of biomarkers for the early diagnosis of *O. volvulus* infections will be an important adjunct during this phase [127]. Finally, a pivotal phase 3 efficacy study would be performed in children examining prophylactic power of the vaccine for registration of the product.

7. Expert opinion

The *O. volvulus* vaccine composed of two antigens *Ov-103* and *Ov-RAL-2* in combination with the adjuvant alum or Advax-2 was shown to be consistently effective at inducing protective immunity and is now the lead vaccine for clinical development. The mechanism of protective immunity induced by the vaccine in mice was dependent on the development of an IgG response. Likewise naturally acquired human antigen-specific monospecific antibodies prevented molting *in vitro* at a statistically significant level. *B. malayi* orthologues of the two vaccine antigens also induced antibodies in gerbils that killed larvae *in vitro* and significantly prevented the development of adult worms and fecundity in the developed female worms. The vaccine is composed of two antigens inoculated as a co-administration or as a fusion vaccine. Each antigen can induce protective immunity independently or as a synergized protective response when combined. Although alum is an effective adjuvant in mice with these vaccine antigens, we selected Advax-2 as the adjuvant for further analysis as it induced both Th1 and Th2 responses similar to that seen in immune humans and protected cows. The adjuvanted vaccines elicited immune responses that proved to be essential for the uniform success of the vaccine in genetically diverse mice, where each protected CC-RIX line responded uniquely to the vaccine. The absence of an IgE antibody response in vaccinated mice and antigen-specific functional IgE responses to each of the vaccine antigens in young children suggests that the vaccine will be safe and effective in children. Although killing of challenge parasites was not absolute in the animal model systems, the vaccine still has clinical applicability assuming that it will result in ~50% decrease in worm burden as it does in mice leading to decreases in disease and transmission. It is also possible that in humans the vaccine-induced protective immune response will be more effective because the challenge infection doses are much smaller – as found in nature – or because the time for the adaptive immune response to kill the new infections has been extended beyond the limited time in mice. Even in the absence of sterilizing immunity, any reduction in the number of adult worms that develop and/or cause significant detrimental effect on the fecundity of the developed female worms will ultimately result in decreased pathology and transmission. The current pre-clinical testing of the *Onchocerca* vaccine

comprised of the two lead vaccine antigens in mice, cows, and non-human primates will lead us within the next few years to the clinical testing of the vaccine in humans.

Funding

This paper was not funded.

Declaration of interest

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Author contributions

All authors have been involved in writing and editing conceived manuscript.

ORCID

David Abraham  <http://orcid.org/0000-0003-3072-2541>

References

Papers of special note have been highlighted as either of interest (*) or of considerable interest (**) to readers.

- Hotez PJ, Alvarado M, Basanez MG, et al. The global burden of disease study 2010: interpretation and implications for the neglected tropical diseases. *PLoS Negl Trop Dis*. 2014 Jul;8(7):e2865.
- Global Burden of Disease Study C. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the global burden of disease study 2013. *Lancet*. 2015 Aug 22;386(9995):743-800.
- Vinkes Melchers NVS, Stolk Wa, Van Loon W, et al. The burden of skin disease and eye disease due to onchocerciasis in countries formerly under the African Programme for Onchocerciasis control mandate for 1990, 2020, and 2030. *PLoS Negl Trop Dis*. 2021 Jul;15(7):e0009604.
- World Health Organization; 2019. [cited 2021 Sep 14]. Available from: <https://www.cdc.gov/parasites/onchocerciasis/epi.html>
- Raimon S, Dusabimana A, Abd-Elfarg G, et al. High prevalence of epilepsy in an Onchocerciasis-Endemic area in Mvolo County, South Sudan: a Door-To-Door survey. *Pathogens*. 2021 May 14;10(5):599-615.
- Brady MA, Hooper PJ, Ottesen EA. Projected benefits from integrating NTD programs in sub-Saharan Africa. *Trends Parasitol*. 2006 Jul;22(7):285-291.
- Boatin BA, Richards FO Jr. Control of onchocerciasis. *Adv Parasitol*. 2006;61:349-394.
- Winnen M, Plaisier AP, Alley ES, et al. Can ivermectin mass treatments eliminate onchocerciasis in Africa? *Bull World Health Organ*. 2002;80(5):384-391.
- Lakwo T, Oguttu D, Ukety T, et al. Onchocerciasis elimination: progress and Challenges 2020 [cited 11] 2020/10/30:[81-95]. Available from: <https://www.ncbi.nlm.nih.gov/pubmed/33117052>
- Hopkins AD. Neglected tropical diseases in Africa: a new paradigm. *Int Health*. 2016 Mar;8(Suppl 1):i28-33.
- Smith ME, Bilal S, Lakwo TL, et al. Accelerating river blindness elimination by supplementing MDA with a vegetation "slash and clear" vector control strategy: a data-driven modeling analysis. *Sci Rep*. 2019 Oct 24;9(1):15274.
- Group NTDMCO. The World Health Organization 2030 goals for onchocerciasis: insights and perspectives from mathematical modelling: NTD modelling consortium Onchocerciasis group. *Gates Open Res*. 2019;3:1545.
- Zoure HG, Wanji S, Noma M, et al. The geographic distribution of Loa loa in Africa: results of large-scale implementation of the Rapid Assessment Procedure for Loiasis (RAPLOA). *PLoS Negl Trop Dis*. 2011 Jun;5(6):e1210.
- Cano J, Basanez MG, O'Hanlon SJ, et al. Identifying co-endemic areas for major filarial infections in sub-Saharan Africa: seeking synergies and preventing severe adverse events during mass drug administration campaigns. *Parasit Vectors*. 2018 Jan 31;11(1):70.
- Kelly-Hope LA, Cano J, Stanton MC, et al. Innovative tools for assessing risks for severe adverse events in areas of overlapping Loa loa and other filarial distributions: the application of micro-stratification mapping. *Parasit Vectors*. 2014 Jul;3(7):307.
- Molyneux DH, Hopkins A, Bradley MH, et al. Multidimensional complexities of filariasis control in an era of large-scale mass drug administration programmes: a can of worms. *Parasit Vectors*. 2014 Aug;15(7):363.
- Milton P, Hamley JID, Walker M, et al. Moxidectin: an oral treatment for human onchocerciasis. *Expert Rev Anti Infect Ther*. 2020 Nov;18(11):1067-1081.
- Duke BO, Moore PJ. The contributions of different age groups to the transmission of Onchocerciasis in a Cameroon forest village. *Trans R Soc Trop Med Hyg*. 1968;62(1):22-28.
- Abraham D, Lucius R, Trees AJ. Immunity to Onchocerca spp. in animal hosts. *Trends Parasitol*. 2002 Apr;18(4):164-171.
- Njongmeta LM, Nfon CK, Gilbert J, et al. Cattle protected from onchocerciasis by ivermectin are highly susceptible to infection after drug withdrawal. *Int J Parasitol*. 2004 Aug;34(9):1069-1074.
- Kohler P. The biochemical basis of anthelmintic action and resistance. *Int J Parasitol*. 2001 Apr;31(4):336-345.
- Huang YJ, Prichard RK. Identification and stage-specific expression of two putative P-glycoprotein coding genes in Onchocerca volvulus. *Mol Biochem Parasitol*. 1999 Aug 20;102(2):273-281.
- Ardelli BF, Guerriero SB, Prichard RK. Genomic organization and effects of ivermectin selection on Onchocerca volvulus P-glycoprotein. *Mol Biochem Parasitol*. 2005 Sep;143(1):58-66.
- Bourguinat C, Pion SD, Kamgno J, et al. Genetic polymorphism of the beta-tubulin gene of Onchocerca volvulus in ivermectin naive patients from Cameroon, and its relationship with fertility of the worms. *Parasitology*. 2006 Feb;132(Pt 2):255-262.
- Eng JK, Prichard RK. A comparison of genetic polymorphism in populations of Onchocerca volvulus from untreated- and ivermectin-treated patients. *Mol Biochem Parasitol*. 2005 Aug;142(2):193-202.
- Awadzi K, Attah SK, Addy ET, et al. Thirty-month follow-up of sub-optimal responders to multiple treatments with ivermectin, in two onchocerciasis-endemic foci in Ghana. *Ann Trop Med Parasitol*. 2004 Jun;98(4):359-370.
- Awadzi K, Boakye DA, Edwards G, et al. An investigation of persistent microfilaridermias despite multiple treatments with ivermectin, in two onchocerciasis-endemic foci in Ghana. *Ann Trop Med Parasitol*. 2004 Apr;98(3):231-249.
- Osei-Atweneboana MY, Eng JK, Boakye DA, et al. Prevalence and intensity of Onchocerca volvulus infection and efficacy of ivermectin in endemic communities in Ghana: a two-phase epidemiological study. *Lancet*. 2007 Jun 16;369(9578):2021-2029.
- Bourguinat C, Pion SD, Kamgno J, et al. Genetic selection of low fertile Onchocerca volvulus by ivermectin treatment. *PLoS Negl Trop Dis*. 2007 Aug 30;1(1):e72.

30. Campbell WC, Fisher MH, Stapley EO, et al. Ivermectin: a potent new antiparasitic agent. *Science*. 1983 Aug 26;221(4613):823–828.
31. Dull HB, Meredith SE. The Mectizan donation programme—a 10-year report. *Ann Trop Med Parasitol*. 1998 Apr;92(Suppl 1):S69–71.
32. Churcher TS, Pion SD, Osei-Atweneboana MY, et al. Identifying sub-optimal responses to ivermectin in the treatment of River Blindness. *Proc Natl Acad Sci U S A*. 2009 Sep 29;106(39):16716–16721.
33. Wolstenholme AJ, Evans CC, Jimenez PD, et al. The emergence of macrocyclic lactone resistance in the canine heartworm, *Dirofilaria immitis*. *Parasitology*. 2015 Sep;142(10):1249–1259.
34. Hoerauf A, Mand S, Volkmann L, et al. Doxycycline in the treatment of human onchocerciasis: kinetics of *Wolbachia* endobacteria reduction and of inhibition of embryogenesis in female *Onchocerca* worms. *Microbes Infect*. 2003 Apr;5(4):261–273.
35. Turner HC, Walker M, Lustigman S, et al. Human Onchocerciasis: modelling the Potential long-term consequences of a vaccination programme. *PLoS Negl Trop Dis*. 2015;9(7):e0003938.
- **Modelling study demonstrating the consequences of an effective vaccine on onchocerciasis.**
36. Diawara L, Traore MO, Badji A, et al. Feasibility of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: first evidence from studies in Mali and Senegal. *PLoS Negl Trop Dis*. 2009 Jul 21;3(7):e497.
37. Traore MO, Sarr MD, Badji A, et al. Proof-of-principle of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: final results of a study in Mali and Senegal. *PLoS Negl Trop Dis*. 2012;6(9):e1825.
38. Gustavsen K, Hopkins A, Sauerbrey M. Onchocerciasis in the Americas: from arrival to (near) elimination. *Parasit Vectors*. 2011 Oct;25(4):205.
39. Kim YE, Remme JH, Steinmann P, et al. Control, elimination, and eradication of river blindness: scenarios, timelines, and ivermectin treatment needs in Africa. *PLoS Negl Trop Dis*. 2015 Apr;9(4):e0003664.
40. Keenan JD, Hotez PJ, Amza A, et al. Elimination and eradication of neglected tropical diseases with mass drug administrations: a survey of experts. *PLoS Negl Trop Dis*. 2013;7(12):e2562.
41. Hoerauf A, Buttner DW, Adjei O, et al. Onchocerciasis. *BMJ*. 2003 Jan 25;326(7382):207–210.
42. Hoerauf A. More research needed to consolidate achievements in filariasis control. *Med Microbiol Immunol*. 2003 Feb;192(1):1–2.
43. Jawahar S, Tricoche N, Bulman CA, et al. Drugs that target early stages of *Onchocerca volvulus*: a revisited means to facilitate the elimination goals for onchocerciasis. *PLoS Negl Trop Dis*. 2021 Feb;15(2):e0009064.
44. Colebunders R, Siewe Fodjo JN, Hopkins A, et al. From river blindness to river epilepsy: implications for onchocerciasis elimination programmes. *PLoS Negl Trop Dis*. 2019 Jul;13(7):e0007407.
45. Hoerauf A, Brattig N. Resistance and susceptibility in human onchocerciasis—beyond Th1 vs. Th2. *Trends Parasitol*. 2002 Jan;18(1):25–31.
46. Richards FO Jr., Boatin B, Sauerbrey M, et al. Control of onchocerciasis today: status and challenges. *Trends Parasitol*. 2001 Dec;17(12):558–563.
47. Cook JA, Steel C, Ottesen EA. Towards a vaccine for onchocerciasis. *Trends Parasitol*. 2001 Dec;17(12):555–558.
48. Nutman TB. Future directions for vaccine-related onchocerciasis research. *Trends Parasitol*. 2002 Jun;18(6):237–239.
49. Dadzie Y, Neira M, Hopkins D. Final report of the Conference on the eradicability of Onchocerciasis. *Filaria J*. 2003 Feb 7;2(1):2.
50. Report of the Thirty-Eighth Session of the Technical Consultative Committee (TCC) African Programme for Onchocerciasis Control (APOC), World Health Organization; 2014 2014 Mar 10–14; Ouagadougou, Burkina Faso.
51. Casulli A. New global targets for NTDs in the WHO roadmap 2021–2030. *PLoS Negl Trop Dis*. 2021 May;15(5):e0009373.
52. Hotez PJ, Bottazzi ME, Zhan B, et al. The Onchocerciasis Vaccine for Africa–TOVA–Initiative. *PLoS Negl Trop Dis*. 2015 Jan;9(1):e0003422.
53. Lustigman S, Makepeace BL, Klei TR, et al. *Onchocerca volvulus*: the road from basic biology to a vaccine. *Trends Parasitol*. 2018 Jan;34(1):64–79.
- **A review paper describing the development and selection of recombinant antigens for testing in the Onchocerca vaccine.**
54. Ward DJ, Nutman TB, Zea-Flores G, et al. Onchocerciasis and immunity in humans: enhanced T cell responsiveness to parasite antigen in putatively immune individuals. *J Infect Dis*. 1988 Mar;157(3):536–543.
55. Gallin M, Edmonds K, Ellner JJ, et al. Cell-mediated immune responses in human infection with *Onchocerca volvulus*. *J Immunol*. 1988 Mar 15;140(6):1999–2007.
56. Elson LH, Guderian RH, Araujo E, et al. Immunity to onchocerciasis: identification of a putatively immune population in a hyperendemic area of Ecuador. *J Infect Dis*. 1994 Mar;169(3):588–594.
57. Turaga PS, Tierney TJ, Bennett KE, et al. Immunity to onchocerciasis: cells from putatively immune individuals produce enhanced levels of interleukin-5, gamma interferon, and granulocyte-macrophage colony-stimulating factor in response to *Onchocerca volvulus* larval and male worm antigens. *Infect Immun*. 2000 Apr;68(4):1905–1911.
58. Schulz-Key H. Observations on the reproductive biology of *Onchocerca volvulus*. *Acta Leiden*. 1990;59(1–2):27–44.
59. MacDonald AJ, Turaga PS, Harmon-Brown C, et al. Differential cytokine and antibody responses to adult and larval stages of *Onchocerca volvulus* consistent with the development of concomitant immunity. *Infect Immun*. 2002 Jun;70(6):2796–2804.
60. McCarthy JS, Nutman TB. Perspective: prospects for development of vaccines against human helminth infections. *J Infect Dis*. 1996 Dec;174(6):1384–1390.
61. Lustigman S, James ER, Tawe W, et al. Towards a recombinant antigen vaccine against *Onchocerca volvulus*. *Trends Parasitol*. 2002 Mar;18(3):135–141.
62. Greene BM, Gbakima AA, Albiez EJ, et al. Humoral and cellular immune responses to *Onchocerca volvulus* infection in humans. *Rev Infect Dis*. 1985 Nov-Dec;7(6):789–795.
63. Leke RG, Boto WM, Lando G, et al. Immunity to *Onchocerca volvulus*. Serum mediated leucocyte adherence to infective larvae in vitro. *Trop Med Parasitol*. 1989 Mar;40(1):39–41.
64. Johnson EH, Irvine M, Kass PH, et al. *Onchocerca volvulus*: in vitro cytotoxic effects of human neutrophils and serum on third-stage larvae. *Trop Med Parasitol*. 1994 Dec;45(4):331–335.
65. Ottesen EA. Immune responsiveness and the pathogenesis of human onchocerciasis. *J Infect Dis*. 1995 Mar;171(3):659–671.
66. Soboslay PT, Luder CG, Hoffmann WH, et al. Ivermectin-facilitated immunity in onchocerciasis; activation of parasite-specific Th1-type responses with subclinical *Onchocerca volvulus* infection. *Clin Exp Immunol*. 1994 May;96(2):238–244.
67. Boyer AE, Tsang VC, Eberhard ML, et al. Guatemalan human onchocerciasis. II. Evidence for IgG3 involvement in acquired immunity to *Onchocerca volvulus* and identification of possible immune-associated antigens. *J Immunol*. 1991 Jun 1;146(11):4001–4010.
68. Stewart GR, Elson L, Araujo E, et al. Isotype-specific characterization of antibody responses to *Onchocerca volvulus* in putatively immune individuals. *Parasite Immunol*. 1995 Jul;17(7):371–380.
69. Soboslay PT, Geiger SM, Weiss N, et al. The diverse expression of immunity in humans at distinct states of *Onchocerca volvulus* infection. *Immunology*. 1997 Apr;90(4):592–599.
70. Faulkner H, Gardon J, Kamgno J, et al. Antibody responses in onchocerciasis as a function of age and infection intensity. *Parasite Immunol*. 2001 Sep;23(9):509–516.
71. Duke BO. Observations on *Onchocerca volvulus* in experimentally infected chimpanzees. *Tropenmed Parasitol*. 1980 Mar;31(1):41–54.
72. Eberhard ML, Dickerson JW, Tsang VC, et al. *Onchocerca volvulus*: parasitologic and serologic responses in experimentally infected chimpanzees and mangabey monkeys. *Exp Parasitol*. 1995 May;80(3):454–462.

73. Abraham D, Lange AM, Yutanawiboonchai W, et al. Survival and development of larval *Onchocerca volvulus* in diffusion chambers implanted in primate and rodent hosts. *J Parasitol.* **1993** Aug;79(4):571–582.
74. Lustigman S, MacDonald AJ, Abraham D. CD4+-dependent immunity to *Onchocerca volvulus* third-stage larvae in humans and the mouse vaccination model: common ground and distinctions. *Int J Parasitol.* **2003** Sep 30;33(11):1161–1171.
- **Proof of concept that the mechanism of protective immunity in mice and humans to *O. volvulus* is shared.**
75. Bain O. [The genus *Onchocerca*: hypothesis on its evolution and a key to the species (author's transl)]. *Ann Parasitol Hum Comp.* **1981**;56(5):503–526.
76. Bwangamoi O. *Onchocerca ochengi* new species, an intradermal parasite of cattle in East Africa. *Bull Epizoot Dis Afr.* **1969** Sep;17(3):321–335.
77. Wahl G, Schibel JM. *Onchocerca ochengi*: morphological identification of the L3 in wild *Simulium damnosum* s.l., verified by DNA probes. *Parasitology.* **1998** Apr;116(Pt 4):337–348.
78. Bandi C, Anderson TJ, Genchi C, et al. Phylogeny of *Wolbachia* in filarial nematodes. *Proc Biol Sci.* **1998** Dec 22;265(1413):2407–2413.
79. Bain O. Evolutionary Relationships Among Filarial Nematodes. The Filaria. Boston MA: Springer US; **2002**. p. 21–29.
80. Krueger A, Fischer P, Morales-Hojas R. Molecular phylogeny of the filaria genus *Onchocerca* with special emphasis on Afrotropical human and bovine parasites. *Acta Trop.* **2007** Jan;101(1):1–14.
81. Morales-Hojas R, Cheke RA, Post RJ. A preliminary analysis of the population genetics and molecular phylogenetics of *Onchocerca volvulus* (Nematoda: filarioidea) using nuclear ribosomal second internal transcribed spacer sequences. *Mem Inst Oswaldo Cruz.* **2007** Nov;102(7):879–882.
82. Graham SP, Wu Y, Henkle-Duehrsen K, et al. Patterns of *Onchocerca volvulus* recombinant antigen recognition in a bovine model of onchocerciasis. *Parasitology.* **1999** Dec;119(Pt 6):603–612.
83. Hoch BWG, Enyong P, Lüder CG, et al. Onchocerciasis of cattle and man: serological recognition of parasite specific and cross-reactive antigens. *Parasite.* **1994**;1:514.
84. Wahl G, Enyong P, Ngosso A, et al. *Onchocerca ochengi*: epidemiological evidence of cross-protection against *Onchocerca volvulus* in man. *Parasitology.* **1998** Apr;116(Pt 4):349–362.
85. Trees AJ. *Onchocerca ochengi*: mimic, model or modulator of *O. volvulus*? *Parasitol Today.* **1992** Oct;8(10):337–339.
86. Makepeace BL, Tanya VN. 25 years of the *Onchocerca ochengi* model. *Trends Parasitol.* **2016** Dec;32(12):966–978.
87. Trees AJ, Wahl G, Klager S, et al. Age-related differences in parasitosis may indicate acquired immunity against microfilariae in cattle naturally infected with *Onchocerca ochengi*. *Parasitology.* **1992** Apr;104(Pt 2):247–252.
88. Hildebrandt JC, Eisenbarth A, Renz A, et al. Reproductive biology of *Onchocerca ochengi*, a nodule forming filarial nematode in zebu cattle. *Vet Parasitol.* **2014** Sep 15;205(1–2):318–329.
89. Tchakoute VL, Graham SP, Jensen SA, et al. In a bovine model of onchocerciasis, protective immunity exists naturally, is absent in drug-cured hosts, and is induced by vaccination. *Proc Natl Acad Sci U S A.* **2006** Apr 11;103(15):5971–5976.
- **Evidence of natural and vaccine protective immunity against *O. ochengi* in cattle.**
90. Wahl G, Achukwi MD, Mbah D, et al. Bovine onchocercosis in north Cameroon. *Vet Parasitol.* **1994** Apr;52(3–4):297–311.
91. Wahl G, Ekale D, Schmitz A. *Onchocerca ochengi*: assessment of the *Simulium* vectors in north Cameroon. *Parasitology.* **1998** Apr;116(Pt 4):327–336.
92. Eisenbarth A, Achukwi MD, Renz A. Ongoing transmission of *Onchocerca volvulus* after 25 years of annual Ivermectin mass treatments in the Vina du Nord river valley, in North Cameroon. *PLoS Negl Trop Dis.* **2016** Feb;10(2):e0004392.
93. Boussinesq M, Enyong P, Chounna-Ndongmo P, et al. Effects of an injectable long-acting formulation of ivermectin on *Onchocerca ochengi* in zebu cattle. *Parasite.* **2020**;27:36.
94. Langworthy NG, Renz A, Mackenstedt U, et al. Macrofilaricidal activity of tetracycline against the filarial nematode *Onchocerca ochengi*: elimination of *Wolbachia* precedes worm death and suggests a dependent relationship. *Proc Biol Sci.* **2000** Jun 7;267(1448):1063–1069.
95. Makepeace BL, Jensen SA, Laney SJ, et al. Immunisation with a multivalent, subunit vaccine reduces patent infection in a natural bovine model of onchocerciasis during intense field exposure. *PLoS Negl Trop Dis.* **2009** Nov 10;3(11):e544.
- **Proof of concept for recombinant antigen vaccine induced protection against *O. ochengi* in cattle.**
96. Achukwi MD, Harnett W, Bradley J, et al. *Onchocerca ochengi* acquisition in zebu Gudali cattle exposed to natural transmission: parasite population dynamics and IgG antibody subclass responses to Ov10/Ov11 recombinant antigens. *Vet Parasitol.* **2004** Jun 10;122(1):35–49.
97. Achukwi MD, Harnett W, Enyong P, et al. Successful vaccination against *Onchocerca ochengi* infestation in cattle using live *Onchocerca volvulus* infective larvae. *Parasite Immunol.* **2007** Mar;29(3):113–116.
98. Nimmerjahn F, Bruhns P, Horiuchi K, et al. FcγR4: a novel FcR with distinct IgG subclass specificity. *Immunity.* **2005** Jul;23(1):41–51.
99. Estes DM, Closser NM, Allen GK. IFN-γ stimulates IgG2 production from bovine B cells costimulated with anti-μ and mitogen. *Cell Immunol.* **1994** Apr 1;154(1):287–295.
100. Lange AM, Yutanawiboonchai W, Lok JB, et al. Induction of protective immunity against larval *Onchocerca volvulus* in a mouse model. *Am J Trop Med Hyg.* **1993** Dec;49(6):783–788.
101. Lange AM, Yutanawiboonchai W, Scott P, et al. IL-4- and IL-5-dependent protective immunity to *Onchocerca volvulus* infective larvae in BALB/cBYJ mice. *J Immunol.* **1994** Jul 1;153(1):205–211.
102. Johnson EH, Schnyder-Candrian S, Rajan TV, et al. Immune responses to third stage larvae of *Onchocerca volvulus* in interferon-γ and interleukin-4 knockout mice. *Parasite Immunol.* **1998** Jul;20(7):319–324.
103. Yutanawiboonchai W, Brigandi RA, Rotman HL, et al. Structural and molecular specificity of antibody responses in mice immune to third stage larvae of *Onchocerca volvulus*. *Parasite Immunol.* **1996** Feb;18(2):95–102.
104. Abraham D, Leon O, Schnyder-Candrian S, et al. Immunoglobulin E and eosinophil-dependent protective immunity to larval *Onchocerca volvulus* in mice immunized with irradiated larvae. *Infect Immun.* **2004** Feb;72(2):810–817.
105. Hess JA, Zhan B, Bonne-Annee S, et al. Vaccines to combat river blindness: expression, selection and formulation of vaccines against infection with *Onchocerca volvulus* in a mouse model. *Int J Parasitol.* **2014** Aug;44(9):637–646.
- **Identification of Ov-103 and Ov-RAL-2 as lead vaccine candidate antigens.**
106. Arumugam S, Wei J, Liu Z, et al. Vaccination of Gerbils with Bm-103 and Bm-RAL-2 Concurrently or as a fusion protein confers consistent and improved protection against *Brugia malayi* infection. *PLoS Negl Trop Dis.* **2016** Apr;10(4):e0004586.
- **Bm-103 and Bm-RAL-2 protect gerbils against infection with *Brugia malayi* and reduces female worm fecundity.**
107. Abraham D, Leon O, Leon S, et al. Development of a recombinant antigen vaccine against infection with the filarial worm *Onchocerca volvulus*. *Infect Immun.* **2001** Jan;69(1):262–270.
108. George PJ, Hess JA, Jain S, et al. Antibody responses against the vaccine antigens Ov-103 and Ov-RAL-2 are associated with protective immunity to *Onchocerca volvulus* infection in both mice and humans. *PLoS Negl Trop Dis.* **2019** Sep;13(9):e0007730.
- **Description of the role antibody plays in immunity to *O. volvulus* in humans and mice.**
109. Petrovsky N, Cooper PD. Advax, a novel microcrystalline polysaccharide particle engineered from delta inulin, provides robust adjuvant potency together with tolerability and safety. *Vaccine.* **2015** Nov 4;33(44):5920–5926.

110. Hess JA, Zhan B, Torigian AR, et al. The Immunomodulatory role of adjuvants in vaccines formulated with the recombinant antigens Ov-103 and Ov-RAL-2 against *Onchocerca volvulus* in mice. *PLoS Negl Trop Dis*. 2016 Jul;10(7):e0004797.
- **Selection of optimal adjuvant for use in *Onchocerca* vaccine**
111. Diemert DJ, Pinto AG, Freire J, et al. Generalized urticaria induced by the Na-ASP-2 hookworm vaccine: implications for the development of vaccines against helminths. *J Allergy Clin Immunol*. 2012 Jul;130(1):169–76 e6.
112. Hamilton RG, MacGlashan DW Jr., Saini SS. IgE antibody-specific activity in human allergic disease. *Immunol Res*. 2010 Jul;47(1–3):273–284.
113. Ryan NM, Hess JA, de Villena FP, et al. *Onchocerca volvulus* bivalent subunit vaccine induces protective immunity in genetically diverse collaborative cross recombinant inbred intercross mice. *NPJ Vaccines*. 2021 Jan 26;6(1):17.
- **Demonstration tha the *Onchocerca* vaccine functions in widely diverse mouse strains.**
114. Nfon CK, Makepeace BL, Njongmeta LM, et al. Lack of resistance after re-exposure of cattle cured of *Onchocerca ochengi* infection with oxytetracycline. *Am J Trop Med Hyg*. 2007 Jan;76(1):67–72.
115. Golden O, Flynn RJ, Read C, et al. Protection of cattle against a natural infection of *Fasciola hepatica* by vaccination with recombinant cathepsin L1 (rFhCL1). *Vaccine*. 2010 Aug 2;28(34):5551–5557.
116. Graham-Brown J, Hartley C, Clough H, et al. Dairy Heifers naturally exposed to *Fasciola hepatica* develop a Type 2 immune response and concomitant suppression of leukocyte proliferation. *Infect Immun*. 2018;86(1):Jan.
117. Garcia-Campos A, Correia CN, Naranjo-Lucena A, et al. *Fasciola hepatica* infection in cattle: analyzing responses of Peripheral Blood Mononuclear Cells (PBMC) using a transcriptomics approach. *Front Immunol*. 2019;10:2081.
118. Naqid IA, Owen JP, Maddison BC, et al. Mapping polyclonal antibody responses to bacterial infection using next generation phage display. *Sci Rep*. 2016 Apr;13(6):24232.
119. Holenya P, Lange PJ, Reimer U, et al. Peptide microarray-based analysis of antibody responses to SARS-CoV-2 identifies unique epitopes with potential for diagnostic test development. *Eur J Immunol*. 2021 Mar 27;51:1839–1849.
120. Orr MT, Khandhar AP, Seydoux E, et al. Reprogramming the adjuvant properties of aluminum oxyhydroxide with nanoparticle technology. *NPJ Vaccines*. 2019;4:1.
121. Desbien AL, Reed SJ, Bailor HR, et al. Squalene emulsion potentiates the adjuvant activity of the TLR4 agonist, GLA, via inflammatory caspases, IL-18, and IFN-gamma. *Eur J Immunol*. 2015 Feb;45(2):407–417.
122. Mestas J, Hughes CC. Of mice and not men: differences between mouse and human immunology. *J Immunol*. 2004 Mar 1;172(5):2731–2738.
123. Reed SG, Orr MT, Fox CB. Key roles of adjuvants in modern vaccines. *Nat Med*. 2013 Dec;19(12):1597–1608.
124. Siddiqui AJ, Molehin AJ, Zhang W, et al. Sm-p80-based vaccine trial in baboons: efficacy when mimicking natural conditions of chronic disease, praziquantel therapy, immunization, and *Schistosoma mansoni* re-encounter. *Ann N Y Acad Sci*. 2018 Aug;1425(1):19–37.
125. Karmakar S, Zhang W, Ahmad G, et al. Cross-species protection: *Schistosoma mansoni* Sm-p80 vaccine confers protection against *Schistosoma haematobium* in hamsters and baboons. *Vaccine*. 2014 Mar 5;32(11):1296–1303.
126. Maslow JN. Challenges and solutions in the development of vaccines against emerging and neglected infectious diseases. *Hum Vaccin Immunother*. 2019;15(10):2230–2234.
127. Bennuru S, Oduro-Boateng G, Osigwe C, et al. Integrating multiple biomarkers to increase sensitivity for the detection of *Onchocerca volvulus* Infection. *J Infect Dis*. 2020 May 11;221(11):1805–1815.